We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Podcast Highlights: Should Investors Forget the Obamacare Battle and Focus on HealthTech Stocks Instead?
Read MoreHide Full Article
For Immediate Release
Chicago, IL – While Washington continues to debate Obamacare and the AHCA, investors interested in the health care market are puzzled about what to focus on next in this important sector. Fortunately, in this week’s Dutram Report, we focus in on a key area of the health care world which is likely to grow in importance no matter what happens with politics. Check it out for more information! To listen to the podcast, click here: ( https://www.zacks.com/stock/news/256403/health-care-and-technology-a-perfect-combo-for-stock-investors-now )
When you try to talk to investors about the health care sector these days, the discussion inevitably leads to the ongoing battle over Obamacare and the AHCA. The future is very uncertain for this sector, and investors have seen some volatile trading for ETFs tracking the broad market, such as (XLV - Free Report) , or worries over pricing issues for funds in the biotech sector, like (IBB - Free Report) .
And given the ongoing discussion for this sector, it is hard to say what the final outcome will be for Americans, or the stocks tracking this key market either.
How to Play This Situation
One thing that isn’t going to change about the health care industry going forward, however, is its continued adoption of technology. The health care world has been a bit slow to adopt new technological practices, but the area is finally coming on strong as of late.
Honestly, it is about time, as the area is definitely long overdue for a technological shakeup. Still, it can be hard to separate the areas of this market with high potential, and those that are just a passing fad. After all, there are plenty of buzzwords when it comes to the intersection of technology and health care, and like many things in health care, the jargon can be confusing.
Some of the latest buzzwords that investors have been talking about in this market include informatics, telemedicine, and even ‘cyborgization’, though some of these areas are definitely hitting the mainstream lately. But to get to the bottom of this story and to understand what is really going on with the adoption of technology in the health care world, I spoke with Andrew Chanin, the CEO of PureFunds. His company is probably best-known for its cybersecurity ETF (HACK - Free Report) , but they also have a suite of other sector-focused funds, including the PureFunds ETFx HealthTech ETF .
As such, he was able to shed some light on this interesting topic for the latest edition of the Dutram Report, and clue us in on why this market might be worth focusing in on now.
My Chat with Andrew
In the interview, Andrew and I discuss why it has taken so long for health care companies to adopt technology, and what they are doing about this lack of investment these days. Andrew and I also converse about the prospects of this corner of the market in today’s market environment, and if an Obamacare replacement will be a concern for investors in this area.
We also talk about IMED in a bit greater detail, and we dive into some of the fund holdings, such as Teladoc (TDOC - Free Report) . Additionally, we take a long at the large cap vs. small cap breakdown, noting how this fund might differ from some out there that are just focused on medical devices and companies like (MDT - Free Report) , and how PureFunds’ IMED—which includes both device stocks like (ISRG - Free Report) but also more software-oriented plays such as (MDRX - Free Report) —could be a bit different for investors.
Lastly, we discuss how this might be an area for investors to focus on for growth, and what some of those buzzwords I mentioned earlier mean for investors right now. In particular, this idea of cyborgization could have transformative effects for many people out there, but that is really only the tip of the iceberg in this quickly-growing, but little-discussed health tech market.
Bottom Line
Andrew and I also talk about why numerous companies are focusing in on this corner of the health care market now, and what investors need to know about how this sort of strategy might fit into a portfolio too. So, if you have been unsure of what to do with your health care investments in light of the legislative uncertainty, this podcast is definitely a must-listen.
But do you think health tech is the next hot area for investors in this sector? Listen to this edition of the Dutram Report and be the judge yourself. And make sure to write us in at podcast @ zacks.com or find me on twitter @EricDutram to let me know what you think of this interview, and health care investing as well.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros .
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Podcast Highlights: Should Investors Forget the Obamacare Battle and Focus on HealthTech Stocks Instead?
For Immediate Release
Chicago, IL – While Washington continues to debate Obamacare and the AHCA, investors interested in the health care market are puzzled about what to focus on next in this important sector. Fortunately, in this week’s Dutram Report, we focus in on a key area of the health care world which is likely to grow in importance no matter what happens with politics. Check it out for more information! To listen to the podcast, click here: ( https://www.zacks.com/stock/news/256403/health-care-and-technology-a-perfect-combo-for-stock-investors-now )
When you try to talk to investors about the health care sector these days, the discussion inevitably leads to the ongoing battle over Obamacare and the AHCA. The future is very uncertain for this sector, and investors have seen some volatile trading for ETFs tracking the broad market, such as (XLV - Free Report) , or worries over pricing issues for funds in the biotech sector, like (IBB - Free Report) .
And given the ongoing discussion for this sector, it is hard to say what the final outcome will be for Americans, or the stocks tracking this key market either.
How to Play This Situation
One thing that isn’t going to change about the health care industry going forward, however, is its continued adoption of technology. The health care world has been a bit slow to adopt new technological practices, but the area is finally coming on strong as of late.
Honestly, it is about time, as the area is definitely long overdue for a technological shakeup. Still, it can be hard to separate the areas of this market with high potential, and those that are just a passing fad. After all, there are plenty of buzzwords when it comes to the intersection of technology and health care, and like many things in health care, the jargon can be confusing.
Some of the latest buzzwords that investors have been talking about in this market include informatics, telemedicine, and even ‘cyborgization’, though some of these areas are definitely hitting the mainstream lately. But to get to the bottom of this story and to understand what is really going on with the adoption of technology in the health care world, I spoke with Andrew Chanin, the CEO of PureFunds. His company is probably best-known for its cybersecurity ETF (HACK - Free Report) , but they also have a suite of other sector-focused funds, including the PureFunds ETFx HealthTech ETF .
As such, he was able to shed some light on this interesting topic for the latest edition of the Dutram Report, and clue us in on why this market might be worth focusing in on now.
My Chat with Andrew
In the interview, Andrew and I discuss why it has taken so long for health care companies to adopt technology, and what they are doing about this lack of investment these days. Andrew and I also converse about the prospects of this corner of the market in today’s market environment, and if an Obamacare replacement will be a concern for investors in this area.
We also talk about IMED in a bit greater detail, and we dive into some of the fund holdings, such as Teladoc (TDOC - Free Report) . Additionally, we take a long at the large cap vs. small cap breakdown, noting how this fund might differ from some out there that are just focused on medical devices and companies like (MDT - Free Report) , and how PureFunds’ IMED—which includes both device stocks like (ISRG - Free Report) but also more software-oriented plays such as (MDRX - Free Report) —could be a bit different for investors.
Lastly, we discuss how this might be an area for investors to focus on for growth, and what some of those buzzwords I mentioned earlier mean for investors right now. In particular, this idea of cyborgization could have transformative effects for many people out there, but that is really only the tip of the iceberg in this quickly-growing, but little-discussed health tech market.
Bottom Line
Andrew and I also talk about why numerous companies are focusing in on this corner of the health care market now, and what investors need to know about how this sort of strategy might fit into a portfolio too. So, if you have been unsure of what to do with your health care investments in light of the legislative uncertainty, this podcast is definitely a must-listen.
But do you think health tech is the next hot area for investors in this sector? Listen to this edition of the Dutram Report and be the judge yourself. And make sure to write us in at podcast @ zacks.com or find me on twitter @EricDutram to let me know what you think of this interview, and health care investing as well.
But for more news and discussion regarding the world of ETFs, make sure to be on the lookout for the next edition of the Dutram Report , and check out the many other great Zacks podcasts as well!
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros .
Follow Eric on Twitter: https://twitter.com/ericdutram
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
podcast@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.